NASDAQ: ITOCItonic Holdings Ltd Stock
$0.61-0.29 (-32.22%)
Updated Jan 16, 2026
ITOC Price
$0.61
Fair Value Price
$0.44
Market Cap
$10.38M
52 Week Low
$0.39
52 Week High
$32.00
P/E
-3.71x
P/B
2.19x
P/S
904.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$305.22k
Earnings
-$2.41M
Gross Margin
82.9%
Operating Margin
-789.48%
Profit Margin
-790.6%
Debt to Equity
0.08
Operating Cash Flow
N/A
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ITOC Overview
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ITOC's potential to beat the market
- ITOC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ITOC
RankedUnranked of 100
RankedUnranked of 100
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $13.79 | A | |
| $30.46 | A | |
| $7.93 | A |
Be the first to know about important ITOC news, forecast changes, insider trades & much more!
ITOC News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ITOC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ITOC ($0.61) is overvalued by 38.24% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ITOC ($0.61) is not significantly undervalued (38.24%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ITOC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ITOC due diligence checks available for Premium users.
Valuation
ITOC fair value
Fair Value of ITOC stock based on Discounted Cash Flow (DCF)
Price
$0.61
Fair Value
$0.44
Overvalued by
38.47%
ITOC ($0.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ITOC ($0.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ITOC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ITOC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.71x
Industry
23.65x
Market
46.6x
ITOC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.19x
Industry
3.86x
ITOC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ITOC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ITOC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.1M
Liabilities
$382.6k
Debt to equity
0.08
ITOC's short-term assets ($4.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITOC's short-term assets ($4.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITOC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ITOC vs Medical Device Stocks
Itonic Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.